Table 1 Characteristics of people with CF who received a CT-based body composition analysis at baseline and after initiation of ETI therapy.
n = 66 | Baseline (T0) | ETI (T1) | p value |
|---|---|---|---|
Age, years | 35 (27.75; 42.5) | ||
Female sex, n (%) | 31 (47) | ||
FEV1 (% predicted) | 37 (28; 49.5) | 47.5 (36.25; 63) | < 0.001 |
FEV1 [L] | 1.35 (0.97; 1.9) | 1.70 (1.22; 2.27) | < 0.001 |
BMI, kg/m2 | 19.5 (18; 21.95) | 21.8 (20; 23.75) | < 0.001 |
Underweight, n (%) | 20 (30) | 5 (8) | 0.003 |
Normal, n (%) | 40 (61) | 52 (79) | |
Overweight, n (%) | 5 (8) | 9 (14) | |
Body weight, kg | 58 (52, 64) | 62 (57, 72) | < 0.001 |
Body height, m | 1.73 (1.65; 1.77) | 1.72 (1.64, 1.77) | 0.500 |
Body surface area, m2 | 1.68 (1.58; 1.79) | 1.71 (1.61; 1.89) | < 0.001 |
Sweat chloride, mmol/L* | 102 (92.5; 110) | 46 (39; 63) | < 0.001 |
CFTR genotype, n (%) | |||
Homozygous dF508 | 38 (58) | ||
Heterozygous dF508 | 25 (38) | ||
Other** | 3 (5) | ||
Prior CFTR modulator therapy, n (%) | |||
Mono-/dual-combination*** | 33 (50) | ||
None | 33 (50) | ||
Chest CT scan | |||
Before/after ETI, days | 52 (0;209.25) | 529 (357.75; 648.25) | |
Indication for CT scan, n (%) | 0.999 | ||
Pulmonary exacerbation | 10 (15) | 9 (14) | |
Hemoptysis | 3 (5) | 4 (6) | |
Other (elective CT scan)**** | 53 (80) | 53 (80) | |
